Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Stemtech (STEK) EBITDA (2020 - 2025)

Stemtech (STEK) has disclosed EBITDA for 6 consecutive years, with -$127115.0 as the latest value for Q3 2025.

  • Quarterly EBITDA rose 94.37% to -$127115.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$145406.0 through Sep 2025, up 97.74% year-over-year, with the annual reading at -$4.1 million for FY2024, 17.74% up from the prior year.
  • EBITDA hit -$127115.0 in Q3 2025 for Stemtech, down from $389146.0 in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $17.0 million in Q3 2022 to a low of -$24.6 million in Q2 2022.
  • Historically, EBITDA has averaged -$1.4 million across 5 years, with a median of -$639252.0 in 2024.
  • Biggest YoY gain for EBITDA was 393.92% in 2022; the steepest drop was 8215.81% in 2022.
  • Year by year, EBITDA stood at -$584502.0 in 2021, then skyrocketed by 84.14% to -$92699.0 in 2022, then plummeted by 1208.61% to -$1.2 million in 2023, then surged by 130.16% to $365863.0 in 2024, then tumbled by 134.74% to -$127115.0 in 2025.
  • Business Quant data shows EBITDA for STEK at -$127115.0 in Q3 2025, $389146.0 in Q2 2025, and -$773300.0 in Q1 2025.